Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase 1 Study of Dazukibart (PF-06823859) in Healthy Subjects
NCT02766621Phase 1Completed
- Sponsor
- Pfizer
- Start
- May 2016
- Primary completion
- Aug 2017
- Modality
- Monoclonal Antibodies
- Countries
- 1
01
Overview
Phase 1, randomised, double-blind trial in dermatomyositis (DM), polymyositis (PM) and systemic lupus erythematosus (SLE) comparing Placebo with PF-06823859 (2 arms). Primary endpoint: Number of Participants With Treatment Emergent Treatment-Related Adverse Events at Day 189. Started May 2016; status: completed.
02
Drugs
dazukibart
03
Conditions
dermatomyositis (DM)polymyositis (PM)systemic lupus erythematosus (SLE)
Beyond the preview
Go deeper on NCT02766621.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02766621.